furazolidone has been researched along with Gastroduodenal Ulcer in 14 studies
Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with Helicobacter pylori positive peptic ulcer disease were randomly allocated into two groups: amoxicillin 1 g b." | 9.15 | Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. ( Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A, 2011) |
| "Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB-M-F; metronidazole (M) (500 mg bid) for the first 5 days, followed by furazolidone (F) (200 mg bid) for the second 5 days; OAC-P; clarithromycin (C) (500 mg bid) for 10 days; and OAB-C-F; clarithromycin (500 mg bid) for the first 5 days and furazolidone (200 mg bid) for the second 5 days." | 9.14 | Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. ( Agah, S; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Pourshams, A; Riahizadeh, S; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2010) |
| "To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success." | 9.13 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. ( Barbuti, RC; Eisig, JN; Felga, GE; Navarro-Rodriguez, T; Silva, FM; Zaterka, S, 2008) |
| "Patients with Helicobacter pylori positive peptic ulcer disease were randomly allocated into two groups: amoxicillin 1 g b." | 5.15 | Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. ( Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A, 2011) |
| "Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB-M-F; metronidazole (M) (500 mg bid) for the first 5 days, followed by furazolidone (F) (200 mg bid) for the second 5 days; OAC-P; clarithromycin (C) (500 mg bid) for 10 days; and OAB-C-F; clarithromycin (500 mg bid) for the first 5 days and furazolidone (200 mg bid) for the second 5 days." | 5.14 | Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. ( Agah, S; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Pourshams, A; Riahizadeh, S; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2010) |
| "To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success." | 5.13 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. ( Barbuti, RC; Eisig, JN; Felga, GE; Navarro-Rodriguez, T; Silva, FM; Zaterka, S, 2008) |
| " pylori) is complex; full effectiveness is rarely achieved and it has many adverse effects." | 2.78 | Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. ( Barbuti, RC; Bogsan, CS; Chinzon, D; de Oliveira, MN; Eisig, JN; Mattar, R; Moraes-Filho, JP; Navarro-Rodriguez, T; Silva, FM, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (42.86) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Navarro-Rodriguez, T | 2 |
| Silva, FM | 3 |
| Barbuti, RC | 3 |
| Mattar, R | 1 |
| Moraes-Filho, JP | 1 |
| de Oliveira, MN | 1 |
| Bogsan, CS | 1 |
| Chinzon, D | 1 |
| Eisig, JN | 3 |
| Felga, GE | 1 |
| Zaterka, S | 1 |
| Xu, C | 1 |
| Xiao, L | 1 |
| Zou, H | 1 |
| Riahizadeh, S | 1 |
| Malekzadeh, R | 1 |
| Agah, S | 1 |
| Zendehdel, N | 1 |
| Sotoudehmanesh, R | 1 |
| Ebrahimi-Dariani, N | 1 |
| Pourshams, A | 1 |
| Vahedi, H | 1 |
| Mikaeli, J | 1 |
| Khatibian, M | 1 |
| Massarrat, S | 1 |
| Ghadir, MR | 1 |
| Shafaghi, A | 1 |
| Iranikhah, A | 1 |
| Pakdin, A | 1 |
| Joukar, F | 1 |
| Mansour-Ghanaei, F | 1 |
| Wang, F | 1 |
| Wang, XY | 1 |
| Jia, Y | 1 |
| Shen, SR | 1 |
| Xu, CX | 1 |
| Tang, WL | 1 |
| Liu, SJ | 1 |
| Chen, X | 1 |
| Rodriguez, TN | 1 |
| Hashimoto, CL | 1 |
| Zheng, ZT | 3 |
| Xiao, SD | 1 |
| Liu, WZ | 1 |
| Hu, PJ | 1 |
| Xia, DH | 1 |
| Tytgat, GN | 1 |
| Wang, ZY | 2 |
| Chu, YX | 2 |
| Li, YN | 2 |
| Li, QF | 2 |
| Lin, SR | 2 |
| Xu, ZM | 2 |
| Zhao, HY | 1 |
| Li, GZ | 1 |
| Guo, JD | 1 |
| Yan, Z | 1 |
| Sun, SW | 1 |
| Li, LS | 1 |
| Duan, YM | 1 |
| Yue, FZ | 1 |
| Howden, A | 1 |
| Boswell, P | 1 |
| Tovey, F | 1 |
| Shi, AS | 1 |
1 review available for furazolidone and Gastroduodenal Ulcer
| Article | Year |
|---|---|
[Advances in clinical observations and experimental research on peptic ulcer treated with traditional Chinese medicine and western medicine].
Topics: Acupuncture Therapy; Animals; DNA; Furazolidone; Humans; Medicine, Chinese Traditional; Medicine, Ea | 1985 |
11 trials available for furazolidone and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Brazil; Disease Eradication; Double- | 2013 |
Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dr | 2008 |
[Effect of birid triple viable on peptic ulcer patients with Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug The | 2010 |
Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Double-Blind Meth | 2010 |
Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents | 2011 |
[Five-day rabeprazole-based triple therapy for helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Drug Administrati | 2004 |
[A double-blind short-term clinical trial of furazolidone on peptic ulcer].
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Furazolidone; Gastric Acid; Humans; Ma | 1984 |
High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Cla | 1999 |
Double-blind short-term trial of furazolidone in peptic ulcer.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Furazolidone; Humans; Male; Peptic Ulc | 1985 |
Furazolidone in peptic ulcer.
Topics: Adult; Cimetidine; Female; Furazolidone; Humans; Male; Peptic Ulcer; Pyridoxine; Vitamin K | 1985 |
A double-blind short-term clinical trial of furazolidone on peptic ulcers.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Furazolidone; Humans; Male; Peptic Ulc | 1985 |
2 other studies available for furazolidone and Gastroduodenal Ulcer
| Article | Year |
|---|---|
A furazolidone-based quadruple therapy for Helicobacter pylori retreatment in patients with peptic ulcer disease.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Local; Chi-Square Distribution; Cohort Studies; Conf | 2005 |
In-vitro sensitivity of Campylobacter pyloridis to furazolidone.
Topics: Campylobacter; Furazolidone; Humans; Peptic Ulcer | 1986 |